The two agonists of TIGIT, CD155 (also known as poliovirus receptor [PVR]) and CD112 (alternatively termed as PVRL2 or nectin-2), are widely expressed by immune, non-immune, and tumor cells, including melanoma cells 126. Here, NECTIN2 is linked to neoplasm.